Ausper Biopharma initiates AHB-171 trial for chronic hepatitis B
Ausper Biopharma is conducting an open-label trial to assess the efficacy and safety of AHB-171 in chronic hepatitis B patients.
Company
Pharmaceutical intelligence for Ausper Biopharma with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.